Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Craig S. Owens who wrote (535)	5/12/1999 6:44:00 PM
From: BRAVEHEART	Respond to of 1494

Hi Craig, I'm glad to see the M&M's are getting a little less stingy. Here we are 10+ days later. It looks like NTII has found a new trading range based on the lack of sellers. Looks like 3/4 to $1. John I would guess your theory on the M&M being short is incorrect. There is no way they would pass off shares at $1 if they were. They started to sell shares above 1.25 on that day. Hence any shares they could cover with would be distributed in said manner. Jeffrey

To: Craig S. Owens who wrote (535)	5/17/1999 2:00:00 PM
From: Dr. John M. de Castro	Respond to of 1494

Memantine may be useful for preventing hearing loss. Take your memantine before going to your next rock concert :-) John de C Acta Otolaryngol (Stockh) 1999 Mar;119(2):174-8 New approaches for inner ear therapy with glutamate antagonists. Oestreicher E, Arnold W, Ehrenberger K, Felix D ENT Department, Technical University of Munich, Germany. e.oestreicher@lrz.tu-muenchen.de In the mammalian cochlea neurotransmission between inner hair cells and afferent auditory neurons is probably mediated by glutamate or another related excitatory amino acid. Neurotoxicity induced by excessive glutamate release seems to play a crucial role in some pathological conditions of the cochlea, such as ischaemia or noise trauma. Thus, glutamate antagonists may be a new therapeutic strategy for different inner ear diseases. Because of their potential severe side-effects only a few glutamate antagonists have so far been adopted for clinical use. We used microiontophoretic techniques to compare the effects of memantine and caroverine on the glutamatergic transmission of inner hair cells of the guinea pig and tested the possibility of a local administration of memantine to the cochlea with a micropump. Memantine selectively inhibited the NMDA (N-methyl-D-aspartate) stimulated activity while caroverine blocked NMDA as well as AMPA (alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) induced activity of inner hair cell afferents. With a flow rate of 1 microl/h the local administration of memantine via a cochleotomy was succeeded in a reversible blockade of the spontaneous and the NMDA induced firing of inner hair cell afferents. These results suggest that local application to the cochlea could be a feasible way to administer glutamate antagonists in sufficient amounts while avoiding systemic side-effects.